A triple GIP / GLP-1 / glucagon receptor agonist studied for multi-incretin metabolic signaling.

| Compound | Retatrutide |
| Also known as | LY3437943 |
| CAS Number | 2381089-83-2 |
| Molecular Weight | 4,731.32 g/mol |
| Sequence / Form | Synthetic triple-agonist peptide |
| Classification | Metabolic research compound |
| Appearance | Lyophilized powder |
| Purity | ≥99% (HPLC · MS-verified) |
| Storage | 2–8°C; -20°C for long-term |
| Intended Use | Research Use Only |
Retatrutide is a synthetic triple agonist targeting the GIP, GLP-1, and glucagon receptors simultaneously. Research models investigate the combined contribution of all three pathways to glucose regulation, lipid metabolism, and energy expenditure.
The triple-receptor mechanism distinguishes it as a next-generation incretin research compound and a frequent subject of comparative agonist studies.
Every Ethos Bio lot of Retatrutide is analyzed by reverse-phase HPLC and independently confirmed by mass spectrometry through our third-party testing partner, Janoshik Analytical. A signed Certificate of Analysis documenting identity and ≥99% purity is provided for every lot.
Independent third-party HPLC & mass-spec verification. The COA shipped with your order reflects your specific lot.
What is Retatrutide?
Retatrutide is a synthetic triple agonist of the GIP, GLP-1, and glucagon receptors, studied for multi-incretin metabolic signaling in research models. It is sold for research use only.
How is Retatrutide different from Tirzepatide?
Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptors), while Tirzepatide is a dual agonist (GIP and GLP-1). The added glucagon-receptor activity is the key research distinction.
What is Retatrutide\u2019s molecular weight?
Retatrutide has a molecular weight of approximately 4,731.32 g/mol and CAS number 2381089-83-2.